Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies

Visualitza/ Obre
Data de publicació
2013Autor/a
Ma, Julian K-C.
Chikwamba, Rachel
Haydon, Hugh
Paul, Mathew J.
Pujol Ferrer, Merardo
Ramalingam, Sathishkumar
Rech, Elibio
Rybicki, Edward
Wigdorowitz, Andres
Yang, Dai-Chang
Thangaraj, Harry
Citació recomanada
Ma, Julian K-C.;
Christou, Paul;
Chikwamba, Rachel;
Haydon, Hugh;
Paul, Mathew J.;
Pujol Ferrer, Merardo;
...
Thangaraj, Harry.
(2013)
.
Realising the value of plant molecular pharming to benefit the poor in developing countries and emerging economies.
Plant Biotechnology Journal, 2013, vol. 11, núm. 9, p. 1029-1033.
https://doi.org/10.1111/pbi.12127.
Metadades
Mostra el registre d'unitat completResum
Molecular Pharming, the production of recombinant pharmaceuticals through plant biotechnology,
has the potential to transform the biologics sector of the pharmaceutical industry. More
fascinating however, is how it might be used to improve access to modern medicines, and
improve health of the poor in developing countries and emerging economies. Although
improving global health through molecular pharming has been discussed for at least two
decades, little progress has actually been made. In this manuscript, a four point plan is described
to maximise the opportunity for molecular pharming to provide solutions. These are (i) to identify
and prioritise important drug targets that are relevant to the poor; (ii) to support research and
development partners in low to middle income countries to develop local expertise, transfer
technology and build capacity; (iii) to increase collaboration between regulatory bodies to enable
national regulatory frameworks to be developed in low to middle income countries; and (iv) to
promote intellectual property management approaches that include socially responsible
licensing. An existing case study is described to illustrate how this might be achieved.